High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder

被引:1
|
作者
Kaberg, Martin [1 ,2 ]
Larsson, Simon B. [3 ,4 ]
Jerkeman, Anna [5 ]
Nystedt, Anders [6 ]
Duberg, Ann-Sofi [7 ]
Kovamees, Jan [8 ]
Ydreborg, Magdalena [3 ]
Aleman, Soo [1 ]
Busch, Katharina [8 ,9 ]
Blome, Marianne Alanko [5 ,10 ]
Weiland, Ola [1 ]
Soderholm, Jonas [8 ,9 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Div Infect Dis, Dept Med Huddinge, Stockholm, Sweden
[2] Stockholm Ctr Dependency Disorders, Stockholm Needle Exchange, Stockholm, Sweden
[3] Univ Gothenburg, Sahlgrenska Acad, Dept Infect Dis, Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Dept Addict, Gothenburg, Sweden
[5] Lund Univ, Dept Translat Med, Sect Infect Dis, Malmo, Sweden
[6] Ctr Communicable Dis Control, Lulea, Region Norrbott, Sweden
[7] Orebro Univ, Fac Med & Hlth, Dept Infect Dis, Orebro, Sweden
[8] AbbVie AB, Hemvarnsgatan 9,Box 1523, SE-17129 Stockholm, Sweden
[9] Karolinska Inst, Dept Lab Med, Div Clin Microbiol, Karolinska Univ Hosp, Stockholm, Sweden
[10] Ctr Communicable Dis Control, Solna, Region Skane, Sweden
关键词
Hepatitis C; chronic; substance abuse; liver disease; mortality; VIRUS-INFECTION; HCV INFECTION; DRUG-USE; ANTIVIRAL AGENTS; PEOPLE; ALCOHOL; PARTICIPANTS; REINFECTION; PROGRESSION; PREVALENCE;
D O I
10.1080/00365521.2020.1754456
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: Hepatitis C virus (HCV) is a slowly progressive disease, often transmitted among people who inject drugs (PWID). Mortality in PWID is high, with an overrepresentation of drug-related causes. This study investigated the risk of death in patients with chronic hepatitis C virus (HCV) infection with or without illicit substance use disorder (ISUD). Methods: Patients with HCV were identified using the Swedish National Patient Registry according to the International Classification of Diseases-10 (ICD-10) code B18.2, with <= 5 matched comparators from the general population. Patients with >= 2 physician visits with ICD-10 codes F11, F12, F14, F15, F16, or F19 were considered to have ISUD. The underlying cause of death was analyzed for alcoholic liver disease, non-alcoholic liver disease, liver cancer, drug-related and external causes, non-liver cancers, or other causes. Mortality risks were assessed using the standardized mortality ratio (SMR) with 95% CIs and Cox regression analyses for cause-specific hazard ratios. Results: In total, 38,186 patients with HCV were included, with 31% meeting the ISUD definition. Non-alcoholic liver disease SMRs in patients with and without ISUD were 123.2 (95% CI, 103.7-145.2) and 69.4 (95% CI, 63.8-75.3), respectively. The significant independent factors associated with non-alcoholic liver disease mortality were older age, being unmarried, male sex, and having ISUD. Conclusions: The relative risks for non-alcoholic liver disease mortality were elevated for patients with ISUD. Having ISUD was a significant independent factor for non-alcoholic liver disease. Thus, patients with HCV with ISUD should be given HCV treatment to reduce the risk for liver disease.
引用
收藏
页码:574 / 580
页数:7
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease
    Chinnadurai, Rajkumar
    Ritchie, James
    Green, Darren
    Kalra, Philip A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (03) : 449 - 457
  • [22] Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
    Stepanova, Maria
    Rafiq, Nila
    Makhlouf, Hala
    Agrawal, Ritambhara
    Kaur, Ishmeet
    Younoszai, Zahra
    McCullough, Arthur
    Goodman, Zachary
    Younossi, Zobair M.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (10) : 3017 - 3023
  • [23] Management of non-alcoholic fatty liver disease in patients with sarcopenia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (02) : 221 - 233
  • [24] Oleuropein as a Therapeutic Agent for Non-alcoholic Fatty Liver Disease During Hepatitis C
    Mohammadjavad Sotoudeheian
    SeyedAhmad Hoseini
    Seyed-Mohamad-Sadegh Mirahmadi
    Navid Farahmandian
    Hamidreza Pazoki-Toroudi
    Revista Brasileira de Farmacognosia, 2023, 33 : 688 - 695
  • [25] Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: Just a coincidence?
    Targher, G.
    Chonchol, M.
    Pichiri, I.
    Zoppini, G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2011, 34 (07) : 544 - 551
  • [26] Non-alcoholic fatty liver disease and cardiovascular risk
    Brea, Angel
    Puzo, Jose
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (04) : 1109 - 1117
  • [27] The Development of Chronic Kidney Disease in Japanese Patients with Non-alcoholic Fatty Liver Disease
    Arase, Yasuji
    Suzuki, Fumitaka
    Kobayashi, Mariko
    Suzuki, Yoshiyuki
    Kawamura, Yusuke
    Matsumoto, Naoki
    Akuta, Norio
    Kobayashi, Masahiro
    Sezaki, Hitomi
    Saito, Satoshi
    Hosaka, Tetsuya
    Ikeda, Kenji
    Kumada, Hiromitsu
    Ohmoto, Yuki
    Amakawa, Kazuhisa
    Tsuji, Hiroshi
    Hsieh, Shiun Dong
    Kato, Kazuhisa
    Tanabe, Maho
    Ogawa, Kyoko
    Hara, Shigeko
    Kobayashi, Tetsuro
    INTERNAL MEDICINE, 2011, 50 (10) : 1081 - 1087
  • [28] In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not
    Younossi, Zobair M.
    Otgonsuren, Munkhzul
    Venkatesan, Chapy
    Mishra, Alita
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2013, 62 (03): : 352 - 360
  • [29] The growing burden of non-alcoholic fatty liver disease on mortality
    Cho, Ju-Yeon
    Sohn, Won
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (02) : 374 - 376
  • [30] Gout and risk of non-alcoholic fatty liver disease
    Kuo, C-F
    Yu, K-H
    Luo, S-F
    Chiu, C-T
    Ko, Y-S
    Hwang, J-S
    Tseng, W-Y
    Chang, H-C
    Chen, H-W
    See, L-C
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 (06) : 466 - 471